OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
July 15, 2021
EMA's PRAC has found a possible link to very rare cases of myocarditis and pericarditis after vaccination with Comirnaty and Spikevax COVID-19 vaccines.
After a review of three cases, EMA's PRAC has advised against the use of Janssen’s COVID-19 vaccine in people who have a history of capillary leak syndrome.
EMA's safety committee, PRAC, has concluded that there is no evidence linking the viral vector in Zynteglo to a blood cancer known as acute myeloid leukemia (AML).
July 12, 2021
FDA’s review and approval of Aduhelm triggers controversy and a call for review from within the Agency.
July 02, 2021
The draft revisions of Annex 1 are driven by a quality risk management approach and will provide more clarity and detail for manufacturers.
Five therapeutic candidates for the treatment of COVID-19 are identified as promising by the European Commission.
June 28, 2021
Reports of myocarditis and pericarditis following Pfizer-BioNTech and Moderna vaccinations prompts warnings.
June 25, 2021
FDA has granted breakthrough therapy designation to donanemab, Eli Lilly and Co.’s investigational antibody treatment for Alzheimer’s disease.
June 23, 2021
The European Commission has purchased an additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022.
Ilya Pharma has been granted approval by the Swedish Medical Product Agency and Swedish Ethical Review Authority for initiation of a Phase II clinical trial of its ILP100 gene therapy.